Article Text

Download PDFPDF
Message from the new EULAR President and Steering Group
  1. Annamaria Iagnocco1,
  2. Daniel Aletaha2,
  3. Xenofon Baraliakos3,
  4. Iain B McInnes4
  1. 1 Dipartimento Scienze Cliniche e Biologiche, Università degli Studi di Torino, Torino, Italy
  2. 2 Department of Rheumatology, Medical University of Vienna, Vienna, Austria
  3. 3 Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Bochum, Germany
  4. 4 MVLS College Office, University of Glasgow, Glasgow, UK
  1. Correspondence to Professor Annamaria Iagnocco, Dipartimento Scienze Cliniche e Biologiche, Università degli Studi di Torino, Torino 10124, Italy; annamaria.iagnocco1{at}


The last decade witnessed the ascendancy of rheumatology to become one of the most dynamic and progressive across the fields of medicine. During the COVID-19 pandemic our discipline emerged at the forefront of molecular medicine with the rapid uptake of immune-modulatory therapeutics and depth of immune pathogenesis understanding contributing fundamentally to the COVID-19 response. The European Alliance of Associations for Rheumatology (EULAR) played a fundamental and vital role in this response in guiding rheumatic and musculoskeletal disease (RMD) therapeutics, vaccine use and even treatment innovations in the context of COVID-19 itself. Given this remarkable contribution, it is timely to reflect on EULAR—what is it and for what does it stand? At its core, EULAR represents people with RMDs, including their national societies, health professionals in rheumatology and scientific societies of rheumatology across the European nations. Our mission is to reduce the burden of RMDs on individuals and society and improve the treatment and prevention of RMDs. In this message from the new EULAR President and Steering Group, we present the most relevant activities of EULAR, its strategic aims and the concept of the EULAR family, a fantastic team of people working together across the three pillars of medical, health professional and patient societies.

  • arthritis
  • autoimmunity
  • COVID-19

Statistics from


  • Handling editor Josef S Smolen

  • Contributors AI conceived the work and drafted the manuscript. All authors contributed to the critical revision of the draft, approved the final version of the manuscript and agree to be accountable for all aspects of the work.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.